2025-04-23 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Review

**0. Key Figures Summary:**

LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period, showing a substantially higher cumulative return.  Recent price movements suggest a slightly overbought condition, warranting cautious optimism.  Financials reveal strong profitability and growth.


**1. Performance Comparison:**

Eli Lilly and Co. (LLY) is a pharmaceutical company.  Its cumulative return of 308.58% drastically surpasses the S&P 500's (VOO) cumulative return of 76.31%. The difference is 232.3%, placing it at the 70.9th percentile of its historical relative performance against the S&P 500 based on the provided range (max: 339.1, min: -27.8).

The Alpha and Beta analysis shows consistently high CAGR (Compound Annual Growth Rate) figures, along with generally positive Alpha values indicating outperformance relative to the market benchmark. Beta, representing market sensitivity, varies across the periods but generally suggests above-average volatility.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 140.0% | 76.8% | 126.0% | 0.2 | 743.1 |


**2. Recent Price Movements:**

* **Closing Price:** $827.54
* **5-day Moving Average:** $795.52
* **20-day Moving Average:** $784.45
* **60-day Moving Average:** $832.31

The price is currently above its 5 and 20-day moving averages, suggesting a short-term uptrend. However, it's slightly below its 60-day moving average, indicating some potential for consolidation or a minor correction.  The recent price increase of $1.16 (from $818.02) is a modest gain and doesn't suggest a significant rapid surge.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.435 (Low to Medium Risk)
* **RSI:** 53.05 (Slightly above neutral; not overbought)
* **PPO:** 1.29 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +2.3 (Short-term upward trend)
* **Expected Return (vs. S&P 500):** 80.6% over the long term (2+ years).  This suggests significant outperformance relative to the broader market.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue          |
|------------|--------|-------------------|
| 2024-10-30 | 1.08   | $11.44 Billion   |
| 2024-08-08 | 3.29   | $11.30 Billion   |
| 2024-04-30 | 2.49   | $8.77 Billion    |
| 2023-11-02 | -0.06  | $9.50 Billion    |
| 2024-10-30 | -0.06  | $9.50 Billion    |

Earnings are highly variable, showing significant fluctuations quarter-to-quarter.  The October 2024 data is duplicated and needs clarification.  Further investigation into the cause of the negative EPS is needed for a comprehensive analysis.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $13.53B  | 82.24%        |
| 2024-09-30 | $11.44B  | 81.02%        |
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |
| 2023-12-31 | $9.35B   | 80.88%        |

**Capital and Profitability:**

| Quarter | Equity    | ROE      |
|---------|-----------|----------|
| 2024-12-31 | $14.19B  | 31.07%   |
| 2024-09-30 | $14.24B  | 6.81%    |
| 2024-06-30 | $13.56B  | 21.88%   |
| 2024-03-31 | $12.81B  | 17.51%   |
| 2023-12-31 | $10.77B  | 20.33%   |

The company demonstrates consistently high profit margins and strong revenue growth. ROE shows some volatility but generally indicates good returns on shareholder equity.


**6. Overall Analysis:**

LLY has shown exceptional performance compared to the S&P 500, with strong long-term growth potential.  Financial indicators suggest robust profitability and healthy revenue. However, recent earnings data needs further clarification regarding the duplicated and negative EPS figures.  While technical indicators point towards a positive short-term trend, the price is near its 60-day moving average, suggesting potential consolidation or minor corrections. The high expected return relative to the S&P 500 is promising for long-term investors, but the volatility in earnings and the relatively high beta suggest it's a stock requiring careful monitoring.  Further due diligence, including analysis of the company's product pipeline and competitive landscape, is recommended before making any investment decisions.
